Arvinas unveils research on PROTAC HPK1 degrader at SITC2026

Arvinas unveils research on PROTAC HPK1 degrader at SITC2026
Arvinas to present PROTAC data

Arvinas announced plans to present preclinical data for its PROTAC HPK1 degrader as well as details on the design of its upcoming Phase 1 2 trial at SITC2026 next week.

The company signaled continued advancement in its drug discovery program and early clinical development pipeline.

Arvinas previously announced the first PROTAC protein degrader approval, expanding its portfolio in targeted protein degradation therapies. The company also reinstated its Early Career Researcher Award, offering a $25,000 grant to support emerging scientists in the field, according to an earlier report on the award announcement. These initiatives indicate Arvinas' continued investment in both pipeline development and scientific research.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.